Skip to main content
Nectar Lifesciences Limited logo

Nectar Lifesciences Limited — Investor Relations & Filings

Ticker · NECLIFE ISIN · INE023H01027 LEI · 335800RY4LGC64KN9C05 BSE.NS Manufacturing
Open in API
Filings indexed 538 across all filing types
Latest filing 2025-07-01 Legal Proceedings Report
Country IN India
Listing BSE.NS NECLIFE

About Nectar Lifesciences Limited

https://www.neclife.com/

Nectar Lifesciences Limited is a pharmaceutical organization specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the cephalosporin segment, producing a wide range of oral and sterile products including Cefixime, Cefuroxime Axetil, and Ceftriaxone. Its operations encompass a fully integrated business model supported by large-scale manufacturing facilities that adhere to international regulatory standards such as USFDA and EUGMP. In addition to its core antibiotic portfolio, the company produces menthol and phytochemicals. Nectar Lifesciences serves a global clientele through contract manufacturing and development services, leveraging its research and development capabilities to provide high-quality therapeutic solutions across various international markets.

Recent filings

Filing Released Lang Actions
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 95% confidence The document is a formal letter addressed to stock exchanges referencing Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. It provides an update on pending litigation and orders passed by regulatory or judicial bodies against the company. The content is focused on disclosing legal proceedings and related financial implications, without presenting financial statements or management discussion. The document length is 3936 characters, which is relatively short and primarily serves as a disclosure update. This matches the description of a Legal Proceedings Report (LTR), which covers updates on significant lawsuits or regulatory actions involving the company.
2025-07-01 English
Retirement
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management personnel, specifically the superannuation and cessation of the Chief Operating Officer effective June 30, 2025. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and includes an annexure with details about the change. There are no financial statements, earnings data, or report attachments. The content is clearly about management change disclosure, not a financial report or other filing types. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3605 characters, which is consistent with a management change announcement rather than a full report or earnings release.
2025-06-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice regarding the closure of the trading window for designated persons and their immediate relatives in compliance with SEBI regulations. It references the upcoming declaration of audited and unaudited financial results but does not contain any financial data or results itself. The document is an update/announcement related to trading restrictions ahead of financial disclosures, not the financial report or earnings release itself. The document length is short (2546 characters) and serves as a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance disclosure under SEBI LODR regulations.
2025-06-27 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 95% confidence The document is a letter addressed to stock exchanges referencing Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events. The content details a Show Cause Notice (SCN) issued by a regulatory authority regarding a litigation matter involving the company. It provides specifics about the SCN, the forum issuing it, and the financial implications. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory disclosure about legal proceedings and compliance, not a full legal proceeding report or financial report. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is under 5,000 characters and contains substantive information about litigation, so it is not a mere announcement or certification. Hence, the classification is LTR with high confidence.
2025-06-26 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 95% confidence The document is a letter addressed to stock exchanges referencing Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, which mandates disclosure of material events including litigation updates. The content provides detailed information about a litigation case involving the company, including the Supreme Court order, financial implications, and actions taken. The document is not a full financial report, earnings release, or management discussion but a regulatory disclosure about legal proceedings. It is a formal update on litigation status as required by regulatory authorities. Therefore, the document fits the category of Legal Proceedings Report (LTR). The document length is 4109 characters, which is sufficient for a substantive update rather than a brief announcement or certification.
2025-06-11 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a formal announcement from Nectar Lifesciences Limited regarding changes in the company's board of directors, specifically the expiry of term and resignation of one director and the appointment of another as an additional and whole-time director. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and includes detailed disclosures about the directors as per regulatory requirements. There is no financial data or results presented, nor is there any mention of financial statements or earnings. The document is clearly about board/management changes and related disclosures, fitting the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about the appointments and resignations, not just a brief notice or report publication announcement.
2025-05-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.